Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Idera Pharmaceuticals patents

Patents where

Current Assignee

Name

Idera Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8431544 Compositions for inhibiting gene expression and uses thereof	Patent 8431544 was granted and assigned to Idera Pharmaceuticals on April, 2013 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8431544	April 30, 2013
‌ US Patent 7470674 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides	Patent 7470674 was granted and assigned to Idera Pharmaceuticals on December, 2008 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7470674	December 30, 2008
‌ US Patent 7851453 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides	Patent 7851453 was granted and assigned to Idera Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7851453	December 14, 2010
‌ US Patent 7776834 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides	Patent 7776834 was granted and assigned to Idera Pharmaceuticals on August, 2010 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7776834	August 17, 2010
‌ US Patent 7276489 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends	Patent 7276489 was granted and assigned to Idera Pharmaceuticals on October, 2007 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7276489	October 2, 2007
‌ US Patent 7812000 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends	Patent 7812000 was granted and assigned to Idera Pharmaceuticals on October, 2010 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7812000	October 12, 2010
‌ US Patent 7517862 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends	Patent 7517862 was granted and assigned to Idera Pharmaceuticals on April, 2009 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7517862	April 14, 2009
‌ US Patent 7407944 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends	Patent 7407944 was granted and assigned to Idera Pharmaceuticals on August, 2008 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7407944	August 5, 2008
‌ US Patent 8202850 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends	Patent 8202850 was granted and assigned to Idera Pharmaceuticals on June, 2012 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8202850	June 19, 2012
‌ US Patent 7709617 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy	Patent 7709617 was granted and assigned to Idera Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7709617	May 4, 2010
‌ US Patent 7713535 Modulation of immunostimulatory properties by small oligonucleotide-based compounds	Patent 7713535 was granted and assigned to Idera Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7713535	May 11, 2010
‌ US Patent 9260719 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 9260719 was granted and assigned to Idera Pharmaceuticals on February, 2016 by the United States Patent and Trademark Office.	Idera Pharmaceuticals	Idera Pharmaceuticals	United States Patent and Trademark Office	9260719	February 16, 2016
‌ US Patent 9540651 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 9540651 was granted and assigned to Idera Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Idera Pharmaceuticals	Idera Pharmaceuticals	United States Patent and Trademark Office	9540651	January 10, 2017
‌ US Patent 8486908 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 8486908 was granted and assigned to Idera Pharmaceuticals on July, 2013 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8486908	July 16, 2013
‌ US Patent 8008267 Stabilized immunomodulatory oligonucleotides	Patent 8008267 was granted and assigned to Idera Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8008267	August 30, 2011
‌ US Patent 9096858 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 9096858 was granted and assigned to Idera Pharmaceuticals on August, 2015 by the United States Patent and Trademark Office.	Idera Pharmaceuticals	Idera Pharmaceuticals	United States Patent and Trademark Office	9096858	August 4, 2015
‌ US Patent 8426375 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 8426375 was granted and assigned to Idera Pharmaceuticals on April, 2013 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8426375	April 23, 2013
‌ US Patent 9206430 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 9206430 was granted and assigned to Idera Pharmaceuticals on December, 2015 by the United States Patent and Trademark Office.	Idera Pharmaceuticals	Idera Pharmaceuticals	United States Patent and Trademark Office	9206430	December 8, 2015
‌ US Patent 7884197 Synthetic agonists of TLR9	Patent 7884197 was granted and assigned to Idera Pharmaceuticals on February, 2011 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7884197	February 8, 2011
‌ US Patent 8377898 Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	Patent 8377898 was granted and assigned to Idera Pharmaceuticals on February, 2013 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8377898	February 19, 2013
‌ US Patent 8188261 Stabilized immune modulatory RNA (SIMRA) compounds	Patent 8188261 was granted and assigned to Idera Pharmaceuticals on May, 2012 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8188261	May 29, 2012
‌ US Patent 7354907 Short immunomodulatory oligonucleotides	Patent 7354907 was granted and assigned to Idera Pharmaceuticals on April, 2008 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7354907	April 8, 2008
‌ US Patent 8362233 Stabilized immune modulatory RNA (SIMRA) compounds	Patent 8362233 was granted and assigned to Idera Pharmaceuticals on January, 2013 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	8362233	January 29, 2013
‌ US Patent 7262286 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes	Patent 7262286 was granted and assigned to Idera Pharmaceuticals on August, 2007 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7262286	August 28, 2007
‌ US Patent 7173014 HIV-specific synthetic oligonucleotides and methods of their use	Patent 7173014 was granted and assigned to Idera Pharmaceuticals on February, 2007 by the United States Patent and Trademark Office.		Idera Pharmaceuticals	United States Patent and Trademark Office	7173014	February 6, 2007

Results per page:

73 results

0 selected

73 results

0 selected